GlassScriptPhysician profile
Lisa C Viola
NPI 1508873811
$1,133.90
in general payments reported to CMS, 2019-2025
22 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $44.46 · 2021: $214 · 2022: $50.64 · 2023: $204 · 2024: $88.41 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.54 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Supernus Pharmaceuticals, INC. | $169.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $143.41 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $140.82 | 2021 | |
| Genentech USA, INC. | $84.89 | 2021-2025 | Ocrevus Zunovo |
| Pfizer INC. | $46.23 | 2023-2025 | |
| Allergan, INC. | $44.17 | 2019 | |
| Emd Serono, INC. | $39.09 | 2019-2020 | |
| Horizon Therapeutics Plc | $27.81 | 2023 | Uplizna |
| Eisai INC. | $23.45 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.55 | 2022 | |
| Merz North America, INC. | $19.82 | 2019 | |
| Merz Pharmaceuticals, LLC | $18.06 | 2025 | Inbrija, Xeomin, Ampyra |
| Lundbeck LLC | $16.96 | 2020 | |
| Livanova USA, INC. | $16.32 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $16.11 | 2025 | Uplizna |
| Tanabe Pharma America, INC. | $15.22 | 2024 | |
| Celgene Corporation | $13.73 | 2025 | Zeposia |
| Kyowa Kirin, INC. | $13.23 | 2024 | Nourianz |
| Bio Products Laboratory USA, INC. | $12.90 | 2023 | Gammaplex, Coagadex |
| Teva Pharmaceuticals USA, INC. | $12.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Viola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.